Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intravenous immunoglobulin: adverse reactions and management.

Literature DB >> 18842292

Intravenous immunoglobulin: adverse reactions and management.

Francisco A Bonilla¹.

Abstract

Mesh：

Substances：

Year: 2008 PMID： 18842292 DOI： 10.1016/j.jaci.2008.08.033

Source DB: PubMed Journal: J Allergy Clin Immunol ISSN： 0091-6749 Impact factor: 10.793

Keyword Cloud
Cited

× No keyword cloud information.

25 in total

Review 1. Subcutaneous immunoglobulin: opportunities and outlook.

Authors: S Misbah; M H Sturzenegger; M Borte; R S Shapiro; R L Wasserman; M Berger; H D Ochs
Journal: Clin Exp Immunol Date: 2009-12 Impact factor: 4.330

2. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

Authors: H B Niebur; C M Duff; G F Shear; D Nguyen; T K Alberdi; M J Dorsey; J W Sleasman
Journal: Clin Exp Immunol Date: 2015-07-07 Impact factor: 4.330

3. 6th International Immunoglobulin Symposium: poster presentations.

Authors: E Fernandez-Cruz; S V Kaveri; H-H Peter; A Durandy; N Cantoni; I Quinti; R Sorensen; J B Bussel; M G Danieli; A Winkelmann; J Bayry; F Käsermann; P Späth; M Helbert; A Salama; I N van Schaik; N Yuki
Journal: Clin Exp Immunol Date: 2009-12 Impact factor: 4.330

4. Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy.

Authors: Raffaella Viti; Andrea Marcellusi; Alessandro Capone; Andrea Matucci; Alessandra Vultaggio; Claudio Pignata; Giuseppe Spadaro; Angelo Vacca; Carolina Marasco; Carlo Agostini; Francesco Saverio Mennini
Journal: Clin Drug Investig Date: 2018-10 Impact factor: 2.859

Review 10. Immune Globulin Subcutaneous (Human) 20% (Hizentra^®): A Review in Chronic Inflammatory Demyelinating Polyneuropathy.

Authors: Yvette N Lamb; Yahiya Y Syed; Sohita Dhillon
Journal: CNS Drugs Date: 2019-08 Impact factor: 6.497

Intravenous immunoglobulin: adverse reactions and management.

Review 1. Subcutaneous immunoglobulin: opportunities and outlook.

2. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

3. 6th International Immunoglobulin Symposium: poster presentations.

4. Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy.

Review 5. Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

6. Administering intravenous immunoglobulin during infection is associated with infusion reactions in selected patients.

Review 7. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer.

8. Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study.

9. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.

Review 10. Immune Globulin Subcutaneous (Human) 20% (Hizentra^®): A Review in Chronic Inflammatory Demyelinating Polyneuropathy.

Intravenous immunoglobulin: adverse reactions and management.

Review 1. Subcutaneous immunoglobulin: opportunities and outlook.

2. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

3. 6th International Immunoglobulin Symposium: poster presentations.

4. Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy.

Review 5. Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

6. Administering intravenous immunoglobulin during infection is associated with infusion reactions in selected patients.

Review 7. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer.

8. Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study.

9. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.

Review 10. Immune Globulin Subcutaneous (Human) 20% (Hizentra®): A Review in Chronic Inflammatory Demyelinating Polyneuropathy.

Review 10. Immune Globulin Subcutaneous (Human) 20% (Hizentra^®): A Review in Chronic Inflammatory Demyelinating Polyneuropathy.